Propanc Biopharma Inc. (PPCB) Attends 31st Annual ROTH Conference
Propanc Biopharma (OTCQB: PPCB) is a biopharmaceutical company developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The company has developed a formulation of anti-cancer compounds, which exert several effects designed to control or prevent tumors from recurring and spreading. The company's products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. The company initially intends to target patients with limited remaining therapeutic options for the treatment of solid tumors. In the future, the company intends to develop its lead product candidate, PRP, to treat early stage cancer and pre-cancerous diseases. For more information,…







